MIRM · Mirum Pharmaceuticals, Inc. · Stock research

Current Thesis

A commercial-stage rare-disease franchise is re-rating on stacked, discrete pipeline de-risking rather than on a soft story. The base business is compounding Q1 2026 net product sales of $159.9M (+43% YoY vs $111.6M in Q1 2025), Livmarli at $113.8M, bile-acid medicines at $46.1M and management lifted 2026 net-sales guidance to $660–680M on the May 6 print, driven by U.S. PFIC demand skewing toward older adolescents and adults. On top of that cash-flowing core sits three near-dated regulatory events: a zilurgisertib FOP PDUFA on 2026-09-26, brelovitug HDV Phase 3 topline in 2H26, and a volixibat NDA in H2 2026. Sell-side is chasing the tape six PT raises since June 11 (RBC $148, MS $150, Citizens $146, Wolfe init $145, HC Wainwright $185, JPM $125) with the stock printing an all-time high of $125.75 on 2026-07-02. The narrative is ACCELERATING; the leg being bought is a multi-asset orphan-drug platform de-risking into 2H26 catalysts.

Bullish and bearish views on Mirum Pharmaceuticals, Inc.

The model's bull view on Mirum Pharmaceuticals, Inc. (MIRM), in brief: Guidance raised, not just met. On the 2026-05-06 Q1 print, 2026 net-sales guide moved up to $660–680M; against FY2025 revenue of $521.31M (+54.7% YoY), that implies continued mid-20s%+ top-line growth off a profitable commercial base. Zilurgisertib FOP data is best-in-class.… The bear view: The whole 2H26 is binary-stacked. Zilurgisertib PDUFA (2026-09-26), AZURE-1/AZURE-4 Phase 3 topline, and the volixibat NDA all cluster into one window; any single disappointment re-rates a name that has already tripled. Valuation prices success. Market cap ~$7.45B (+194% off the… Both cases follow in full.

Bull Case

• Guidance raised, not just met. On the 2026-05-06 Q1 print, 2026 net-sales guide moved up to $660–680M; against FY2025 revenue of $521.31M (+54.7% YoY), that implies continued mid-20s%+ top-line growth off a profitable commercial base.
• Zilurgisertib FOP data is best-in-class. Pivotal Phase 2 PROGRESS Cohort 1 results (ENDO 2026, presented 2026-06-14) showed a 99.9% reduction in new heterotopic-ossification lesion volume with durability through Week 48; no new HO lesions in the open-label extension. FDA granted Priority Review with a PDUFA of 2026-09-26 (partnered with Incyte). FOP is ultra-rare (~300 U.S. / ~900 worldwide) orphan pricing power, minimal competition.
• Brelovitug HDV is a second pillar from the Bluejay deal. Phase 2b AZURE-1 hit its primary endpoint with 100% virologic response and ALT normalization at 300mg once-weekly by Week 24. Phase 3 AZURE-1 enrollment and AZURE-4 screening are complete; topline due 2H26; Breakthrough Therapy + PRIME designations support an expedited BLA.
• Volixibat optionality. IBAT inhibitor with positive Phase 2b in primary sclerosing cholangitis; U.S. NDA targeted for H2 2026, extending the IBAT franchise beyond Livmarli into PSC/PBC.
• Flow confirms, doesn't fade. The analyst-PT cluster (six raises, 2026-06-11 → 2026-07-07) landed as price made new highs sell-side catching up to a narrative already in motion, the pattern this playbook exists to ride.

Bear Case

• The whole 2H26 is binary-stacked. Zilurgisertib PDUFA (2026-09-26), AZURE-1/AZURE-4 Phase 3 topline, and the volixibat NDA all cluster into one window; any single disappointment re-rates a name that has already tripled.
• Valuation prices success. Market cap ~$7.45B (+194% off the 52-week low of $50.25) with the stock at $122.13 (2026-07-10) leaves little cushion if a readout slips or the label disappoints.
• Acquisition-driven accounting noise. The Bluejay deal drove a $726.3M in-process R&D charge and a Q1 net loss of $790.2M, or $(13.43)/share; leverage and integration risk sit under the growth story.
• Insider selling into strength. Form 4s around 2026-07-08 show the CEO offloading 20,000 shares post option-exercise and the CFO selling 5,000 under a 10b5-1 plan routine, but not the insider buying that flags fresh conviction.
• Zilurgisertib economics are shared with Incyte the FOP approval is a headline win, but the P&L contribution is split.

Setup & Price Structure

Price closed 2026-07-10 at $122.13, down 4.36% on the day, just under the 2026-07-02 all-time high of $125.75. The 52-week range is $50.25–$130.00, so the name has roughly tripled off its low and trades in the top decile of its range extended, and near round-number resistance at $125–130. The structure is a clean stair-step higher off the 2026-06-14 FOP-data breakout, with the current pullback shallow (~3% off the high). In this playbook, a name pressing all-time highs while sell-side raises targets is confirmation of an ACCELERATING trend, so the stretch above rising averages is the setup, not a reason to stand aside.

Catalyst Calendar (next 30 days)

• ~2026-07-30 (est.) Q2 2026 earnings. Binary for the guidance narrative; watch Livmarli PFIC ramp and any tightening of the $660–680M FY guide. MarketBeat-listed date, treat as estimated until confirmed.
• 2026-09-26 (beyond 30d, but the dominant catalyst) zilurgisertib FOP PDUFA under Priority Review (Incyte partnership).
• 2H 2026 (beyond 30d) brelovitug AZURE-1 + AZURE-4 Phase 3 topline in chronic HDV; forms the basis of the U.S. BLA.
• H2 2026 (beyond 30d) volixibat U.S. NDA submission for PSC.

What Would Change Our Mind

A weekly close below $100 breaks the post-June breakout structure and voids the momentum leg. Secondary thesis-breaks: a brelovitug AZURE-1 Phase 3 topline that misses virologic-response/ALT-normalization on the primary endpoint; a zilurgisertib PDUFA setback around 2026-09-26 (CRL or restrictive label); or a Q2 print that cuts the $660–680M FY guide. A move to SATURATED mainstream retail/CNBC coverage of the "rare-disease multibagger" with no new de-risking event left before 2027 would flip the read from ride to fade.

Correlation Notes

Idiosyncratic, catalyst-driven small/mid-cap biotech beta to SPY/QQQ is secondary to binary event risk. Peer read-through is thin: FOP has no direct listed comparable (competing programs are early), and HDV exposure overlaps loosely with Gilead's bulevirtide franchise as a commercial reference point, not a trading correlate. The name will trade on its own PDUFA/Phase 3 print dates far more than on XBI. Zilurgisertib PnL and FOP-approval optionality are shared with Incyte (INCY), so INCY headlines on the program are a same-direction tell.